Antibody Humanization Services Using Humanization CDRx®

Our proprietary Humanization CDRx® platform combines advanced CDR grafting, intelligent framework selection and structural modelling to generate highly developable humanized antibodies suitable for therapeutic antibody development. Whether you require humanization of mouse or rabbit antibodies, VHH humanization, or support for more complex antibody formats, our experienced antibody engineering scientists work collaboratively to deliver candidates with an exceptionally high probability of success.

Key benefits

• 100% success rate preserving antibody function and affinity
• Mature human framework database containing more than 200,000 antibody sequences
• Humanization completed using IMGT, Chothia or Kabat numbering schemes
• Designs within 2 weeks, with optional experimental validation
• Support for conventional antibodies and non-standard antibody formats

Humanization CDRx®: A Data-Driven Antibody Humanization Platform

Successful antibody humanization requires more than simply replacing framework residues. Structural compatibility, developability and immunogenicity must all be considered to maximise the likelihood of producing a therapeutic candidate.

Fusion's Humanization CDRx® platform applies a multi-stage workflow that combines advanced computational antibody engineering with extensive scientific expertise.

Intelligent Human Framework Selection

Every project begins by identifying the most suitable acceptor framework from a proprietary database containing more than 200,000 mature human antibody sequences.

Unlike approaches that rely solely on germline frameworks, our mature framework strategy increases structural compatibility while reducing the risk of introducing unwanted sequence liabilities.

Framework selection is guided by algorithms that evaluate:

• Sequence similarity
• Structural compatibility
• CDR orientation
• Predicted developability
• Potential T-cell epitopes

This approach enables the preservation of antibody binding while reducing immunogenicity.

Precision CDR Grafting and Back Mutation Design

Following framework selection, complementarity determining regions (CDRs) are transferred using a precision CDR grafting strategy.

Targeted back-mutations are then introduced only where structural analysis indicates they are required to maintain antibody conformation and antigen recognition.

Each design is informed by knowledge gained from:

• 300 successful humanization programmes
• Over 8,000 engineered antibody sequences
• Structural modelling expertise
• Antibody engineering best practice

The result is a focused set of candidates designed to retain affinity while significantly improving developability.

Structural Modelling and Variant Prioritisation

Each project includes computational analysis to evaluate structural integrity before laboratory testing.

Our reports include:

• Homology modelling
• Loop refinement
• RMSD comparison with the parental antibody
• Structural assessment of framework compatibility

Rather than generating hundreds of variants, Humanization CDRx® produces a focused panel of 25 optimised candidates (Top 5 heavy chains × Top 5 light chains), reducing downstream screening while optimizing the probability of identifying successful humanized antibodies.

Optional wet-laboratory validation provides in vitro experimental confirmation of antibody expression, functionality and binding performance.

Broad Species Support

Fusion Antibodies has successfully humanized antibodies originating from numerous species and antibody formats, including:

• Mouse IgG
• Rabbit IgG
• Rat IgG
• Llama VHH antibodies
• Chicken IgY
• Shark IgNAR
• scFv antibody fragments

Our platform also supports specialised applications including:

• Rabbit antibody humanization
• VHH humanization
• Antibody deimmunization
• Caninization
• Felinization
• Equinization
• Lapinization

If your antibody format presents unusual structural challenges, our antibody engineering team develops bespoke humanization strategies tailored to your molecule.

Why Choose Fusion Antibodies for Antibody Humanization?

• Mature Human Framework Database

Humanization CDRx® uses mature human antibody frameworks instead of relying solely on germline sequences, improving structural compatibility and increasing the likelihood of preserving biological activity.

• Experience-Driven Back Mutation Strategy

Targeted back-mutations are informed by extensive project experience and structural analysis, helping preserve affinity while minimising unnecessary sequence changes.

• Early Developability Assessment

Potential sequence liabilities are identified during the design stage, helping reduce risks associated with manufacturability, stability and downstream development.

• Expertise with Challenging Antibody Formats

Our scientists frequently work with antibodies that differ substantially from conventional human IgG molecules, including rabbit antibodies, camelid VHHs and other atypical scaffolds.

• Efficient Candidate Selection

A focused panel of rationally designed variants enables efficient laboratory evaluation while avoiding unnecessary experimental screening.

• Proven Performance
• 100% success preserving function and affinity
• 2-week computational design turnaround
• Optional laboratory validation within 8-weeks of design

Applications

Our antibody humanization services support:

• Therapeutic antibody discovery
• Monoclonal antibody development
• Antibody optimisation
• Lead optimisation
• Preclinical drug discovery
• Biologics development
• Recombinant antibody engineering

Developability assessment

Whether your programme is progressing from antibody discovery into preclinical development or requires optimisation of an existing lead, our scientists can tailor a humanization strategy to meet your objectives.

Partner with an Experienced Antibody Engineering CRO

Antibody humanization is a critical step in transforming promising research antibodies into therapeutic candidates with reduced immunogenicity and improved clinical potential.

Fusion Antibodies combines computational design, antibody engineering expertise and optional laboratory validation to deliver humanized antibodies with a high probability of success.

Talk to our scientists today to discuss your antibody humanization project.